Related Experiment Videos
Pneumonia in children in the developing world: new challenges, new solutions
Anne Schuchat1, Scott F Dowell
1Respiratory Diseases Branch, Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30333, USA. Aschuchat@cdc.gov
Insights
Vaccines for Haemophilus influenzae type b (Hib) and pneumococcal disease are effective against childhood pneumonia. New metrics and surveillance tools are needed to monitor pneumonia control programs in developing countries.
Area of Science:
- Global Health
- Infectious Diseases
- Vaccinology
Background:
- Pneumonia remains a leading cause of death globally, particularly in developing countries.
- While infant mortality has decreased due to improved healthcare access, new pathogens pose ongoing challenges.
- Existing health indicators and surveillance tools require enhancement to address evolving pneumonia threats.
Purpose of the Study:
- To highlight the impact of new vaccines on reducing childhood pneumonia.
- To underscore the need for improved metrics and surveillance for pneumonia control.
- To address economic barriers hindering vaccine access in low-income nations.
Main Methods:
- Review of landmark randomized controlled trials on vaccine efficacy.
- Analysis of global health trends and challenges in pneumonia control.
- Discussion of the requirements for effective pneumonia surveillance systems.
Main Results:
- Haemophilus influenzae type b (Hib) and pneumococcal conjugate vaccines demonstrate significant effectiveness against childhood pneumonia, meningitis, and bacteremic disease.
- Economic obstacles impede the widespread access to these life-saving vaccines in the poorest countries.
- There is a critical need for better metrics and surveillance tools to monitor and manage pneumonia.
Conclusions:
- Vaccination represents a major advancement in combating childhood pneumonia.
- Addressing economic barriers is crucial for equitable vaccine distribution.
- Development of advanced surveillance tools is essential for effective pneumonia control programs and disease burden assessment.
Abstract:
Pneumonia has been a leading cause of death in both developed and developing countries as long as health indicators have been available. Yet the issues of concern for this syndrome are far from static. Improvements in access to health services have lowered infant mortality rates, benefiting children around the world and lowering the fraction of child deaths caused by pneumonia. However, progress has been interrupted repeatedly by the emergence of new pathogens. Landmark randomized controlled trials have now demonstrated the effectiveness of Haemophilus influenzae type b (Hib) and multivalent pneumococcal conjugate vaccines against childhood pneumonia, as well as meningitis and bacteremic disease. Momentum has gathered to tackle long-standing economic obstacles to expand access to new vaccines and programs for the poorest countries of the world. A pressing challenge for the control of pneumonia in developing countries is to identify better metrics for pneumonia. Surveillance tools are needed that will bridge studies of interventions, establish preventable disease burden, and serve as indicators for monitoring new programs.
Related Concept Videos
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:30Pneumonia III: Complications and Assessment
01:29Pneumonia I: Introduction
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:29Pneumonia II: Pathophysiology